ライフサイエンスコーパス: microalbuminuria

1 filtration rate [eGFR] <90 mL/min/1.73 m2 or microalbuminuria).

2 not associate with incident CKD or incident microalbuminuria.

3 line among patients with type 1 diabetes and microalbuminuria.

4 buminuric subjects at baseline progressed to microalbuminuria.

5 ays in the kidney occurs before the onset of microalbuminuria.

6 ccurs in a large proportion of patients with microalbuminuria.

7 th diabetes had normal renal function and no microalbuminuria.

8 rate and among participants with or without microalbuminuria.

9 re reduced in association with prevention of microalbuminuria.

10 ucose tolerance testing or measures of IR or microalbuminuria.

11 ls well below the conventional threshold for microalbuminuria.

12 of 90 ml/min per 1.73 m(2) or greater and no microalbuminuria.

13 treatment effect on insulin sensitivity, and microalbuminuria.

14 sk factors for CKD progression, diabetes and microalbuminuria.

15 e, and strongly inhibited the development of microalbuminuria.

16 ependently associated with the regression of microalbuminuria.

17 rs was not associated with the regression of microalbuminuria.

18 ensive care unit admission for assessment of microalbuminuria.

19 duction in patients with type 1 diabetes and microalbuminuria.

20 and priapism, and cf-PWV was associated with microalbuminuria.

21 le nondiabetic participants, 15.2% exhibited microalbuminuria.

22 ly hypertension and IFG were associated with microalbuminuria.

23 tan on UAER in type 2 diabetic patients with microalbuminuria.

24 iated with a twofold increased prevalence of microalbuminuria.

25 bA(1c) >8% have the highest risk of onset of microalbuminuria.

26 ype 2 diabetes detected on screening to have microalbuminuria.

27 re more insulin resistant than those without microalbuminuria.

28 l, P = 0.059) compared with subjects without microalbuminuria.

29 ess expensive than Micral-Test in ruling out microalbuminuria.

30 aired glucose tolerance, was associated with microalbuminuria.

31 n patients with sickle cell disease (SCD) is microalbuminuria.

32 olume, cystatin C-based eGFR, or the risk of microalbuminuria.

33 low body mass index, impaired cognition, and microalbuminuria.

34 ed against 10 patients with persistent (PMA) microalbuminuria.

35 in American Indians with type 2 diabetes and microalbuminuria.

36 ly decreasing with even low-normal levels of microalbuminuria.

37 n of donors with eGFR <60 mL/min/1.73 m2 and microalbuminuria.

38 rventions to reduce low-grade proteinuria or microalbuminuria.

39 sfunction and even in diabetic patients with microalbuminuria.

40 ther markers was poor, with AUCs of 0.61 for microalbuminuria, 0.49 for uric acid, and 0.58 for eGFR.

41 r transplantation) low-grade proteinuria and microalbuminuria (1) provide information on the graft in

42 rveys (9% using ACR > 30 mg/g for persistent microalbuminuria; 11% in 1988 to 1994 and 12% in 1999 to

43 ariable (higher albumin excretion, including microalbuminuria (25-249 mg/g) and macroalbuminuria (>or

44 re analyzed for racial/ethnic differences in microalbuminuria (30 to 300 mg albumin/g creatinine) and

45 uminuria (<30 mg albumin/g creatinine); II = microalbuminuria (30 to 300 mg/g); and III = macroalbumi

46 0 microg/mg creatinine), and six (15.4%) had microalbuminuria (30-300 microg/mg creatinine).

47 Seven subjects (19.4%) had microalbuminuria (30-300 mug/mg creatinine).

48 Microalbuminuria, a marker of glomerular hyperfiltration

49 The pattern of occurrence of microalbuminuria according to duration of IDDM suggests

50 e patients with type 1 diabetes mellitus and microalbuminuria, ACE inhibitors significantly reduced p

51 /creatinine ratio [ACR] <30 mg/g; n = 91) or microalbuminuria (ACR 30-299 mg/g; n = 78) at baseline.

52 ; hazard ratio, 3.2; 95% CI, 2.3 to 4.5) and microalbuminuria (ACR, 30 to 299 mg/g; hazard ratio, 2.0

53 <20 microg/min), 52 (35 men, 17 women) with microalbuminuria (AER 20-200 microg/min), and 37 (17 men

54 available were studied for the incidence of microalbuminuria (albumin excretion rate [AER] 20-200 mi

55 and fasting plasma insulin concentration, to microalbuminuria (albumin-to-creatinine ratio > or = 2 m

56 group at highest risk for the development of microalbuminuria, albuminuria, and progressive renal dis

57 ate were risk factors for the development of microalbuminuria (all P < 0.05).

58 mong those with retinopathy concomitant with microalbuminuria (all-cause HR, 1.70; 95% CI, 1.03-2.23,

59 djusted A/C underestimated the prevalence of microalbuminuria among men by 52% and among Blacks by 26

60 nce), while 9 (8%), 13 (13%), and 1 (1%) had microalbuminuria, an eGFR less than 90 mL/min/1.73 m2, a

61 (n = 1675 for CKD analyses and n = 1252 for microalbuminuria analyses).

62 Patients with microalbuminuria and 25 yr of postpubertal IDDM have low

63 A/kC >or= 25 mg/g (194 cases of microalbuminuria and 26 cases of clinical grade albuminu

64 re were no differences between patients with microalbuminuria and albuminuria.

65 file associated with type 2 diabetes, reduce microalbuminuria and ameliorate the prothrombotic diathe

66 bolic challenge that obesity represents then microalbuminuria and blunted bilateral renal function re

67 <0.05), but did not associate with childhood microalbuminuria and BP.

68 k, 0.79 [CI, 0.66 to 0.96]) in patients with microalbuminuria and cardiovascular disease or high-risk

69 st circumference is associated with incident microalbuminuria and change in creatinine clearance was

70 albuminuria in men, however, suggesting that microalbuminuria and CHD are not causally related but ra

71 renal function (nondecliners), from 28 with microalbuminuria and early progressive renal function de

72 cement (CE(2)) throughout 9 months prevented microalbuminuria and excess extracellular matrix accumul

73 he relationship between HbA(1c) and onset of microalbuminuria and found significant nonlinearity in t

74 CKD was defined as presence of microalbuminuria and GFR > or =60 ml/min per 1.73 m(2) (

75 er-homocysteinemia (HHcy) is associated with microalbuminuria and glomerular injury in general and di

76 min excretion rate in diabetic patients with microalbuminuria and has anti-inflammatory properties, r

77 Little is known about microalbuminuria and insulin resistance in nondiabetic s

78 diabetes, RAS inhibitors delay the onset of microalbuminuria and its progression to macroalbuminuria

79 ferences exist in the adjusted prevalence of microalbuminuria and macroalbuminuria depending on hyper

80 ed in 28% (n = 58), while the frequencies of microalbuminuria and macroalbuminuria were 45% (n = 64)

81 Racial/ethnic differences in the odds of microalbuminuria and macroalbuminuria were assessed by u

82 arious subgroups, but delayed progression to microalbuminuria and macroalbuminuria, and improved regr

83 The prevalence of microalbuminuria and macroalbuminuria, and the predictiv

84 on during puberty precede the development of microalbuminuria and macroalbuminuria, long-term risk fa

85 an eGFR <60 mL/min/1.73 m(2) , 6 (5.8%) had microalbuminuria and none were on dialysis.

86 dpoint, but for lower levels of albuminuria (microalbuminuria and normoalbuminuria), the evidence is

87 macroalbuminuria, and improved regression to microalbuminuria and normoalbuminuria.

88 ibrate for microvascular endpoints including microalbuminuria and retinopathy.

89 nes the relationship between proteinuria and microalbuminuria and similar factors in ADPKD children.

90 ples were obtained from 43 participants with microalbuminuria and stable renal function (nondecliners

91 s study investigated the association between microalbuminuria and the insulin resistance syndrome (IR

92 ht indicate increased risk of progression to microalbuminuria and then to overt diabetic nephropathy.

93 decline begins in one third of patients with microalbuminuria and type 1 diabetes.

94 Microalbuminuria and urinary 8-iso-PGF2alpha, an index o

95 -25% (-31 to -19; p<0.0001) in patients with microalbuminuria, and -32% (-41 to -23; p<0.0001) in pat

96 iabetes, 155+/-7 ml per minute in those with microalbuminuria, and 124+/-7 ml per minute in those wit

97 %) patients had a normal UACR, 704 (30%) had microalbuminuria, and 257 (11%) had macroalbuminuria.

98 Altogether, 15% of the subjects had microalbuminuria, and 32% had hypertension.

99 104, 20 had normal albumin excretion, 50 had microalbuminuria, and 34 had macroalbuminuria.

100 cebo and 1338 assigned to empagliflozin) had microalbuminuria, and 769 (11%; 260 assigned to placebo

101 phy], left ventricular systolic dysfunction, microalbuminuria, and a reduced ankle-brachial index) in

102 has been shown to improve glucose tolerance, microalbuminuria, and arrhythmias in several experimenta

103 damage such as left-ventricular hypertrophy, microalbuminuria, and cognitive dysfunction takes place

104 % CI, 1.27-3.28) and those with retinopathy, microalbuminuria, and diabetes (all-cause HR, 2.01; 95%

105 he index test, in the methods of quantifying microalbuminuria, and in the cutoff values used.

106 abnormalities, left ventricular hypertrophy, microalbuminuria, and increased oxidative stress, is ref

107 the whole population and with elevated TRV, microalbuminuria, and leg ulcers in SS-Sbeta(0) adults,

108 tral Africa is associated with elevated TRV, microalbuminuria, and leg ulcers, but these vascular com

109 s (ie, transitions between normoalbuminuria, microalbuminuria, and macroalbuminuria) and rate of chan

110 lation, and decreased fibrinolytic activity, microalbuminuria, and platelet abnormalities and endothe

111 Microalbuminuria appeared early in the course of IDDM (6

112 Low-grade proteinuria and microalbuminuria are also predictive of diabetes, cardio

113 Patients with NIDDM and microalbuminuria are more insulin resistant than those w

114 The importance of microalbuminuria as an early marker for the cardiometabo

115 usual care, screening African Americans for microalbuminuria at 10-, 5-, 2-, and 1-year intervals ha

116 the rate declined by 3 percent in those with microalbuminuria at base line (P=0.29) and by 35 percent

117 Even subjects with low eGFR and microalbuminuria at baseline (n=10) maintained stable va

118 suggest that screening African Americans for microalbuminuria at either 5- or 10-year intervals is hi

119 UACR > or =30 mg/g for participants without microalbuminuria at visit 1 or a > or =25% increase in U

120 significant difference in the prevalence of microalbuminuria between men and women was noted when se

121 mes, creatinine and cystatin C blood levels, microalbuminuria, BP, and eGFR.

122 effects were weaker at the lowest levels of microalbuminuria but did not differ according to other b

123 icity remained significantly associated with microalbuminuria but sex did not.

124 bolic syndrome is not clear, we suggest that microalbuminuria, chronic kidney disease, and coronary h

125 Together with testing for microalbuminuria, clinical protocols using cystatin C to

126 factors for CHD morbidity and mortality were microalbuminuria, current smoking, high diastolic blood

127 Microalbuminuria developed in 109 of the 943 individuals

128 e 3 conditions, and we provide evidence that microalbuminuria develops in many patients with metaboli

129 ne (mg) ratio (ACR) (30 microg/mg) to detect microalbuminuria does not account for sex or racial diff

130 The presence of low-grade proteinuria or microalbuminuria early after transplantation must be tak

131 albumin in humans, which contrasts with the microalbuminuria (equivalent to <150 mg/day) seen in the

132 Subjects with microalbuminuria exhibited moderate increases in glomeru

133 e third of patients with type 1 diabetes and microalbuminuria experience an early, progressive declin

134 Microalbuminuria, expressed as the albumin-creatinine ra

135 mate the cost-effectiveness of screening for microalbuminuria followed by treatment with angiotensin-

136 owed patients with normal renal function and microalbuminuria for 10 to 12 yr and classified them int

137 ponding multivariate-adjusted odds ratios of microalbuminuria for participants with 3, 4, and 5 compo

138 d more overt diabetic nephropathy, including microalbuminuria, glomerular basement thickening, mesang

139 Microalbuminuria, glomerular filtration rate, mesangial

140 wer in subjects treated with losartan in the microalbuminuria group (18.8 vs. 25.6%; P = 0.02), but n

141 slope -7.1; range -23.8 to -3.3%/yr) of the microalbuminuria group (P < 0.001).

142 percentage of ADPKD children had significant microalbuminuria (>15 mg/m2 per 24 h in boys and >23 mg/

143 Persistence of microalbuminuria (>30 mg/g) was estimated from repeat vi

144 Subjects with microalbuminuria had a lower degree of insulin sensitivi

145 s a macromolecular "shunt," individuals with microalbuminuria had a shunt size no different from long

146 obesity without excess body weight.Recently, microalbuminuria has been gaining momentum as a componen

147 e multiple determinants of the regression of microalbuminuria has implications for current theories a

148 Markers of renal dysfunction, especially microalbuminuria, have been considered recently as poten

149 hropathy (DN), 10 patients with intermittent microalbuminuria (IMA) matched against 10 patients with

150 participants without diabetes, we identified microalbuminuria in 2.3% of European Americans, 6.0% of

151 nsin-converting enzyme inhibitor therapy for microalbuminuria in adults with SCD.

152 ey have been found to reduce proteinuria and microalbuminuria in both diabetic nephropathy and nondia

153 This study confirms a high prevalence of microalbuminuria in critically ill patients and suggests

154 The development of microalbuminuria in individuals with type 2 diabetes mel

155 sting CHD is also a risk factor for incident microalbuminuria in men, however, suggesting that microa

156 Although the pathogenesis of microalbuminuria in metabolic syndrome is not clear, we

157 actors that predispose to the development of microalbuminuria in NIDDM.

158 relationship between insulin resistance and microalbuminuria in nondiabetic subjects that is partial

159 ed odds ratios of chronic kidney disease and microalbuminuria in participants with the metabolic synd

160 relationship between insulin resistance and microalbuminuria in patients with NIDDM could be due to

161 Frequent regression of microalbuminuria in patients with type 1 diabetes indica

162 Just because microalbuminuria in people without diabetes is a cardiov

163 pathophysiology of low-grade proteinuria or microalbuminuria in renal transplantation.

164 to define microalbuminuria may underestimate microalbuminuria in subjects with higher muscle mass (me

165 A high hemolysis index was associated with microalbuminuria in the whole population and with elevat

166 el was significantly associated with TRV and microalbuminuria in the whole population and with leg ul

167 First Joslin Study of the Natural History of Microalbuminuria in Type 1 Diabetes, a cohort recruited

168 rence predicts the subsequent development of microalbuminuria in type 1 diabetes.

169 In conclusion, although microalbuminuria in type 2 diabetic Pima Indians often h

170 dices of elevated urinary albumin excretion (microalbuminuria) in IDDM.

171 odipine in patients with type 2 diabetes and microalbuminuria, including the subgroup with baseline n

172 Development of microalbuminuria increases the risk for cardiovascular d

173 study included 386 patients with persistent microalbuminuria, indicated by repeated measurements of

174 Microalbuminuria is a risk factor for renal failure, str

175 It is unclear, however, whether microalbuminuria is a risk factor for the development of

176 Microalbuminuria is associated with an increased risk of

177 Microalbuminuria is associated with excess cardiovascula

178 Screening for microalbuminuria is increasingly advocated as a way to d

179 on in patients with low-grade proteinuria or microalbuminuria is not proven, especially in the absenc

180 idence of kidney injury in diabetes is often microalbuminuria, itself also an independent risk marker

181 ed tricuspid regurgitant jet velocity [TRV], microalbuminuria, leg ulcers, priapism, stroke, and oste

182 ating biomarkers to the incidence of CKD and microalbuminuria (MA) in 2345 participants who attended

183 Microalbuminuria (MA) is a strong risk factor for subseq

184 n approximately 80% rate of progression from microalbuminuria (MA) to proteinuria in type 1 diabetic

185 of follow-up, the incidence of eGFR decline, microalbuminuria, macroalbuminuria, and ESRD was 42.0, 4

186 ted the relationship between Hp genotype and microalbuminuria, macroalbuminuria, end-stage renal dise

187 This descriptive analysis reveals that microalbuminuria may hold promise as a predictor of illn

188 Switching to agalsidase-alfa is safe, but microalbuminuria may progress and Fabry-related symptoms

189 nt of retinal abnormalities in patients with microalbuminuria may provide additional value in identif

190 The use of one ACR value to define microalbuminuria may underestimate microalbuminuria in s

191 ice developed mild diabetic nephropathy with microalbuminuria, mesangial matrix expansion, glomerular

192 diabetes equal to that of the subjects with microalbuminuria (n = 12), or clinical nephropathy (n =

193 res (exposure variables) and incident CKD or microalbuminuria (n = 1675 for CKD analyses and n = 1252

194 linically as having early diabetes (n = 10), microalbuminuria (n = 17), normoalbuminuria, despite a d

195 > or = 250 micrograms/min) and patients with microalbuminuria (N = 31) (AER 20 to 250 micrograms/min)

196 uria in individuals with type 1 diabetes and microalbuminuria (n = 312) who were followed for 4 years

197 in the chronic kidney disease (n = 6217) and microalbuminuria (n = 6125) analyses.

198 n analyses restricted to individuals without microalbuminuria (n=1470) and in subgroups with intermed

199 rglycemia, excessive urination, weight loss, microalbuminuria, nephrinuria and display renal histolog

200 pro-brain natriuretic peptide <100 pg/mL, no microalbuminuria, no family history of coronary heart di

201 Microalbuminuria normalized in five patients.

202 glomerular filtration rate (eGFR), incident microalbuminuria (not reported), incident retinopathy, b

203 ty was related to a decreasing prevalence of microalbuminuria (odds ratio = 0.86, 95% CI: 0.79-0.94,

204 mug mL(-1) covering the diagnostic level of microalbuminuria of 30 mug mL(-1).

205 xpression play a role in the pathogenesis of microalbuminuria of DN.

206 However, microalbuminuria of short duration, salutary levels of g

207 ng those at risk is problematic because even microalbuminuria, often used clinically as an indicator

208 he joint effect of retinal abnormalities and microalbuminuria on CVD risk in an Asian cohort.

209 ion effect between retinal abnormalities and microalbuminuria on incident CVD.

210 Sixty-nine percent of the patients had microalbuminuria or clinical proteinuria and 43.3% had a

211 of circulating APOL1 did not associate with microalbuminuria or GFR.

212 Kidney function (GFR), kidney damage (microalbuminuria or greater), and stages of CKD (GFR and

213 ained deterioration from normoalbuminuria to microalbuminuria or macroalbuminuria (HR 0.84, 0.74 to 0

214 with subsequent development of albuminuria (microalbuminuria or macroalbuminuria) or renal impairmen

215 Retinopathy and albuminuria (microalbuminuria or macroalbuminuria) were both absent i

216 persistent protein leakage from the kidney (microalbuminuria or macroalbuminuria).

217 o significant associations were observed for microalbuminuria or macroalbuminuria.

218 1.67; p<0.0001) or from macroalbuminuria to microalbuminuria or normoalbuminuria (HR 1.82, 1.40 to 2

219 Aminoaciduria was not associated with microalbuminuria or proteinuria but was associated with

220 olesterol (OR=2.90 [1.37-6.12]) and previous microalbuminuria (OR=6.42 [1.42-29.11]) were risk factor

221 er, 89% of variation in risk of retinopathy, microalbuminuria, or albuminuria is due to elements of g

222 nctional reserves manifested by proteinuria, microalbuminuria, or isolated reduction in glomerular fi

223 -converting enzyme inhibitors, screening for microalbuminuria, or screening for gross proteinuria.

224 te (AER) at DCCT closeout developed incident microalbuminuria over 5.8 yr of follow-up.

225 both urinary albumin-to-creatinine ratio and microalbuminuria (P < 0.0001 after multivariable adjustm

226 sk of developing retinopathy (P < 0.001) and microalbuminuria (P < 0.001).

227 ensity lipoprotein fraction in patients with microalbuminuria (P < 0.05) and albuminuria (P < 0.05),

228 The complete panel also correlates with microalbuminuria (P = 0.008) and FUR with nephropathy in

229 P<.001 vs GCK) and 21% (95% CI, 13%-32%) had microalbuminuria (P<.001).

230 Microalbuminuria, per se, is related to vascular injury

231 remains so while normal albumin excretion or microalbuminuria persists.

232 versus placebo group in those with baseline microalbuminuria (placebo-corrected adjusted geometric m

233 These results demonstrate that microalbuminuria predicts incident clinical CHD in men w

234 condary outcomes included the development of microalbuminuria, progression of retinopathy, changes in

235 ificantly (p < 0.001) more likely to develop microalbuminuria, proliferative retinopathy, and distal

236 ween prior glycemic control and the onset of microalbuminuria, proliferative retinopathy, and DSP obs

237 The MicroAlbuminuria Reduction With VALsartan (MARVAL) study

238 Retinal microvascular abnormalities and microalbuminuria reflect early systemic microvascular ch

239 y renal function decline depended on whether microalbuminuria regressed, remained stable, or progress

240 M, and which are relevant to renal medicine: microalbuminuria, renal function, renovascular hypertens

241 An early indicator is microalbuminuria resulting from glomerular filtration ba

242 timal management of low-grade proteinuria or microalbuminuria should occur very early after transplan

243 res; electrocardiography; and assessments of microalbuminuria, standard CVD risk factors, sociodemogr

244 primarily driven by the ACR reduction in the microalbuminuria subgroup (8.1-2.3 mg/mmol; P=0.03; n=23

245 nd AER within the subgroups of patients with microalbuminuria suggest that PK could be a marker for p

246 ments, blood pressure, cholesterol, smoking, microalbuminuria testing, or screening for foot pulses r

247 tor was associated with a lower incidence of microalbuminuria than the use of placebo; in the context

248 The hazard ratio for incident microalbuminuria that was associated with each 10-cm gre

249 of this study suggest that, in patients with microalbuminuria, the risk of progression to overt prote

250 nephropathy to include individuals with high microalbuminuria, the strength of this association impro

251 enzyme inhibitors for diabetic patients with microalbuminuria, this strategy requires that providers

252 ary albumin excretion well below the current microalbuminuria threshold predicted the development of

253 elations of low-grade albuminuria (below the microalbuminuria threshold) and incidence of cardiovascu

254 y to experience a sustained improvement from microalbuminuria to normoalbuminuria (hazard ratio [HR]

255 ACEI and ARB to prevent the progression from microalbuminuria to overt albuminuria in both type 1 and

256 that prospectively evaluated the accuracy of microalbuminuria to predict illness severity and/or mort

257 Studies assessing the accuracy of microalbuminuria to predict illness severity on the inte

258 increasing severity from normoalbuminuria to microalbuminuria to proteinuria but with considerable ov

259 hip between hyperglycemia and progression of microalbuminuria to proteinuria in individuals with type

260 c control reduces the risk of progression of microalbuminuria to proteinuria, two recent clinical tri

261 Compared with screening for microalbuminuria, treating all patients was more expensi

262 t baseline (normoalbuminuria: UACR <30 mg/g; microalbuminuria: UACR >/=30 to </=300 mg/g; and macroal

263 In most survival studies in NIDDM, microalbuminuria (urinary albumin excretion rate 20-200

264 t, age, sex, or self-reported hypertension), microalbuminuria (urine albumin to creatinine ratio >30

265 reatinine and cystatin C concentrations, and microalbuminuria using urine albumin:creatinine ratios.

266 ) for the composite outcome in patients with microalbuminuria versus normoalbuminuria was 1.43 (95% C

267 or death were 1.62 (1.32-1.99; p<0.0001) for microalbuminuria versus normoalbuminuria, and 1.76 (1.32

268 and kidney disease, the odds ratio (OR) for microalbuminuria was 1.8 (95% confidence interval [CI],

269 rmoalbuminuria at baseline, the incidence of microalbuminuria was 29% over the 7-year period.

270 The 5-year cumulative incidence of microalbuminuria was 6% in the placebo group; the incide

271 Microalbuminuria was a significant risk factor for both

272 on rate less than 60 mL/min per 1.73 m2, and microalbuminuria was defined as a urinary albumin-creati

273 Microalbuminuria was defined as urinary albumin: creatin

274 Regression of microalbuminuria was frequent, with a six-year cumulativ

275 Progression to microalbuminuria was less frequent with carvedilol than

276 or the boundary between normoalbuminuria and microalbuminuria was obtained by searching for a cutpoin

277 The risk of onset of microalbuminuria was predicted somewhat more precisely b

278 nt in 6.7% (181 of 2682) of participants and microalbuminuria was present in 8.2% (479 of 5818).

279 CK patients nor controls had proteinuria and microalbuminuria was rare (GCK, 1% [95% CI, 0.2%-6%]; co

280 association between insulin sensitivity and microalbuminuria was shown not to be different between n

281 When a single ACR is used, the prevalence of microalbuminuria was significantly lower among the men c

282 Among those without hypertension, microalbuminuria was twofold greater (odds ratio [OR] 2.

283 esenting with both retinal abnormalities and microalbuminuria were 6.71 times (95% CI, 2.68, 16.79) a

284 with normoalbuminuria and 301 patients with microalbuminuria were followed for 8 to 12 yr.

285 ng those with hypertension, adjusted odds of microalbuminuria were greater for Hispanics (OR 3.82; 95

286 ure, glomerular filtration rate, and urinary microalbuminuria were not.

287 ethnic differences in prevalence of diabetic microalbuminuria were observed in a large primary care p

288 -Asian (n = 9) and white (n = 9) origin with microalbuminuria were studied under euglycemic condition

289 rease in UACR for participants with baseline microalbuminuria) were evaluated by using logistic regre

290 to 1.61) were independently associated with microalbuminuria when a single ACR threshold was used.

291 ds, averaged, and analyzed for regression of microalbuminuria, which was defined as a 50 percent redu

292 s study sought to compare the association of microalbuminuria with outcomes in patients with differen

293 Because microalbuminuria with progression to ESRD is a complicat

294 sociations between retinal abnormalities and microalbuminuria with risk of CVD, while controlling for

295 thirty-two patients with type 2 diabetes and microalbuminuria, with or without hypertension, were ran

296 and burn patients, but not medical patients, microalbuminuria within 15 mins of intensive care unit a